Pfizer Inc (PFE) FinancialsPFEPfizer Inc

Pfizer Inc. (PFE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Eliquis alliance revenues and direct sales, accounting for 16.1% of total sales, equivalent to $2.42B. Other significant revenue streams include Vyndaqel family and Prevnar family. Understanding this composition is critical for investors evaluating how PFE navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Pfizer Inc. maintains a gross margin of 67.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 31.77%, while the net margin is -1.64%. These profitability ratios, combined with a Return on Equity (ROE) of 4.99%, provide a clear picture of how effectively PFE converts its operational activities into shareholder value.

In the context of the broader market, PFE competes directly with industry leaders such as AZN and VRTX. With a market capitalization of $166.49B, it holds a significant position in the sector. When comparing efficiency, PFE's gross margin of 67.81% stands against AZN's 81.25% and VRTX's 85.33%. Such benchmarking helps identify whether Pfizer Inc. is trading at a premium or discount relative to its financial performance.

Pfizer's total revenue for FY 2025 was approximately $62.6 billion, with a net income of around $7.8 billion, reflecting a strong market presence despite a slight decline in revenue year-over-year. The gross margin stands at 67.81%, indicating solid profitability.